Publications

Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH

 59
Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH

Tags:

Previous Article

Blood test can to identify cancer in patients with non-specific symptoms

Next Article

New drug candidate reverses metabolic liver disease and fibrosis

Related Posts

Voluntary exercise sensitizes cancer immunotherapy via the collagen inhibition- orchestrated inflammatory tumor immune microenvironment

Voluntary exercise sensitizes cancer immunotherapy via...

 121

Hippo signaling pathway regulates Ebola virus transcription and egress

Hippo signaling pathway regulates Ebola virus transcrip...

 138

Convection enhanced delivery of Rhenium ( 186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial

Convection enhanced delivery of Rhenium ( 186Re) Obisbe...

 109